Leukapheresis Market End User, Application, Region, Drivers, Product and Leading Players Asahi Kasei Medical Co. Ltd., Fresenius SE & Co. KGaA, Haemonetics Corporation, Terumo BCT, Inc., Macopharma SA

The Leukapheresis Market report clearly explains what market definition, classifications, applications, engagements, and market trends are for the Medical Devices industry. This market study estimates the market status, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors. This global market research report is a professional and detailed report focusing on primary and secondary drivers, market share, leading segments, and geographical analysis. Analysis and estimation of important industry trends, market size, and market share are mentioned in the Leukapheresis Market report.

Request for FREE Sample Report: To Know the Impact of COVID-19 on this Industry at: https://www.reportsnreports.com/contacts/requestsample.aspx?name=1612511

Additionally, the Leukapheresis Market report comprises vital aspects of the market that contains industry research, market sizing & forecast, competitive intelligence, market entry strategy, pricing trends, sustainability trends, customer insights, technology evolution, innovation trends, and distribution channel assessment. By attaining an actionable market insight via this market research report, sustainable and profitable business strategies can be built. All the data and information involved in this report is taken from incredibly trustworthy sources such as websites, annual reports of the companies, white papers, journals, newspapers, and mergers. Also, before presenting it to the end-users, all the information is assessed and validated by the expert team members.

The prominent players in the global leukapheresis and leukopaks market are

Asahi Kasei Medical Co. Ltd. (Japan),
Fresenius SE & Co. KGaA (Germany),
Haemonetics Corporation (US),
Terumo BCT, Inc. (US),
Macopharma SA (France),
Miltenyi Biotec (Germany),
Guangzhou Daji Medical Science and Technology Co. Ltd. (China),
MEDICA S.p.A (Italy),
PuriBlood Medical Co. Ltd. (Taiwan),
and Beijing ZKSK Technology Co. Ltd. (China).

Some prominent players in the leukopaks market are

Charles River Laboratories (US),
AllCells, LLC (US),
StemExpress, LLC. (US),
Caltag Medsystems Limited (UK),
Lonza Group AG (Switzerland),
ZenBio (US),
Precision for Medicine (US),
BioIVT (US),
Discovery Life Sciences (US),
and Intelligent Tissue Group (US).

The global leukaphereis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%.

Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis and cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.

“The leukapheresis disposables segment holds the highest market share, by product, in the leukapheresis products market, in the forecast period.”

On the basis of product, the leukapheresis market is broadly segmented into leukapheresis disposables and leukaphersis devices. Leukapheresis devices are further segmented into centrifugal devices and membrane separators. The large share of the leukapheresis disposables segment can be attributed to the recurrent use of disposables during leukapheresis procedures, increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.

“The centrifugal devices segment to grow at the highest CAGR in the leukapheresis devices market, in the forecast period.”

Based on type, the leukapheresis devices market is broadly segmented into centrifugal devices and membrane separators. Centrifugal devices segment is expected to grow at the higest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis.

“Increasing adoption of leukapheresis products for development of cell-based immunotherapies to promote the growth of this segment in the forecast period.”

Based on application, the leukapheresis products market is segmented into research and therapeutic applications. The research applications segment accounted for the largest share of the leukapheresis products market during the forecast period. The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies and leukapheresis-derived primary cells in drug development.

“In the leukapheresis products market by end user segment, blood component providers & blood centers segment holds the highest market share”

On the basis of end user, the leukapheresis products market is segmented into blood component providers & blood centers, academic and research institutes, pharmaceutical & biotechnology companies, hospitals & transfusion centers. Blood component providers & blood centers hold the largest share in this market. The large share of this segment can be attributed to growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.

“In the leukopaks market by type, the diseased leukopaks segment is projected to grow at the highest rate in forecast period”

Based on type, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.

“Acute Lymphocytic Leukemia holds the largest share in the leukopaks market, by indication, in the forecast period”

Based on indication, the leukopaks market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer, and other indications (colorectal cancer, neuroblastoma, breast cancer, and acute myeloid leukemia). The acute lymphocytic leukemia segment accounts for the largest share of the leukopaks market, by indication. The large share of this segment can be attributed to the increasing focus of pharmaceutical companies on the development of leukopak-based cell therapies for the treatment of acute lymphocytic leukemia (ALL) and a high number of CAR T-cell therapy clinical trials for ALL.

“Acute Lymphocytic Leukemia holds the largest share in the leukopaks market, by indication, in the forecast period”

Based on indication, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.

“The pharmaceutical and biotechnology companies segment to grow at the highest CAGR in the leukopaks market, by end user, in the forecast period”

By end user, the leukopaks market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Pharmacuetical and biotechnology companies are projected to grow at the highest CAGR in this market in the forecast period. Thi highest growth rate can be attributed to increasing collaboration of pharmaceutical companies with academic institutes, research centers, and hospitals for new drug development.

“North America holds the largest share in the leukaphereis and leukopaks market, by region, in the forecast period”

The leukapheresis and leukopaks market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The large share of this region can be attributed to the increasing adoption of leukapheresis products for the development of leukoreduced plasma and leukoreduced RBCs, growing adoption of leukopaks as a source of primary cells for research applications, increasing number of clinical trials for the development of CAR T-cell therapy using leukopaks.

A breakdown of the primary participants for the leukapheresis market referred to for this report is provided below:

By Company Type: Tier 1–30%, Tier 2–25%, and Tier 3–45%
By Designation: C-level–40%, Director Level–35%, and Others–25%
By Region: North America–36%, Europe–26%, Asia Pacific–21%, Rest of the World – 17%
A breakdown of the primary participants for the leukopaks market referred to for this report is provided below:

By Company Type: Tier 1–40%, Tier 2–38%, and Tier 3–22%
By Designation: C-level–40%, Director Level–35%, and Others–25%
By Region: North America–39%, Europe–28%, Asia Pacific–22%, Rest of the World – 11%

Research Coverage:

The report analyzes the market for various leukapheresis and leukopaks product and their adoption pattern. It aims at estimating the market size and future growth potential of the global leukapheresis and leukopaks market and different segments such as product, application, indication, end user and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global leukapheresis products and leukopaks market

Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global leukapheresis products and leukopaks market

Market Development: Comprehensive information on the lucrative emerging regions by products, end user, and region

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global leukapheresis products and leukopaks market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the global leukapheresis products and leukopaks market.

Purchase this report (FLAT 20% Discount. Coupon Code: JAN20) at: https://www.reportsnreports.com/purchase.aspx?name=1612511

Table Of Contents

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.2.1 Inclusions And Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered For The Study
1.4 Currency
Table 1 Standard Currency Conversion Rates
1.5 Limitations
1.6 Stakeholders
1.7 Summary Of Changes

2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
Figure 2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Insights From Primary Experts
Figure 3 Breakdown Of Primary Interviews: Supply-Side And Demand-Side Participants (Leukapheresis & Leukopaks Market)
Figure 4 Breakdown Of Primary Interviews: By Company, Designation, And Region (Leukapheresis Market)
Figure 5 Breakdown Of Primary Interviews: By Company Type, Designation, And Region (Leukopaks Market)
2.2 Market Size Estimation: Leukapheresis Market
Figure 6 Supply-Side Market Size Estimation: Revenue Share Analysis
Figure 7 Revenue Share Analysis Illustration
Figure 8 Revenue Analysis Of The Top 4 Companies: Leukapheresis Market (2020)
Figure 9 Cagr Projections: Supply-Side Analysis (Leukapheresis Market)
Figure 10 Top-Down Approach
2.3 Market Size Estimation: Leukopaks Market
Figure 11 Volume Estimation Of Leukopaks Market
Figure 12 Cagr Projections: Supply-Side Analysis (Leukopaks Market)
Figure 13 Top-Down Approach
2.4 Market Breakdown & Data Triangulation
Figure 14 Market Data Triangulation Methodology
2.5 Market Share Analysis
2.6 Assumptions For The Study
2.7 Risk Assessment
Table 2 Risk Assessment: Leukapheresis & Leukopaks Market
2.8 Covid-19 Health Assessment
2.9 Covid-19 Economic Assessment
2.10 Assessment Of The Impact Of Covid-19 On The Economic Scenario
Figure 15 Criteria Impacting The Global Economy
Figure 16 Recovery Scenario Of The Global Economy
2.11 Assessment Of The Impact Of Covid-19 On The Economic Scenario In The Leukapheresis And Leukopaks Market

3 Executive Summary
Figure 17 Leukapheresis Products Market, By Type, 2021 Vs. 2026 (Usd Million)
Figure 18 Leukapheresis Devices Market, By Type, 2021 Vs. 2026 (Usd Million)
Figure 19 Leukapheresis Products Market, By Application, 2021 Vs. 2026 (Usd Million)
Figure 20 Leukapheresis Products Market, By End User, 2021 Vs. 2026 (Usd Million)
Figure 21 Leukopaks Market, By Type, 2021 Vs. 2026 (Usd Million)
Figure 22 Leukopaks Market, By Indication, 2021 Vs. 2026 (Usd Million)
Figure 23 Leukopaks Market, By End User, 2021 Vs. 2026 (Usd Million)
Figure 24 Geographic Snapshot: Leukapheresis Products Market
Figure 25 Geographic Snapshot: Leukopaks Market

4 Premium Insights
4.1 Leukapheresis Products Market Overview
Figure 26 Increasing Incidence And Prevalence Of Leukemia To Drive Market Growth
4.2 North America: Leukapheresis Products Market, By Type And Country
Figure 27 Leukapheresis Disposables Commanded The Largest Share Of The North American Leukapheresis Products Market In 2020
4.3 Leukapheresis Products Market: Geographic Mix
Figure 28 China To Witness The Highest Growth In The Leukapheresis Products Market During The Forecast Period
4.4 Regional Mix: Leukapheresis Products Market
Figure 29 North America Dominated The Market In 2020
4.5 Leukopaks Market Overview
Figure 30 Favorable Government Support And Rising Demand For Leukopaks In Research Applications To Drive Market Growth
4.6 North America: Leukopaks Market, By Product And Country
Figure 31 Mobilized Leukopaks Commanded The Largest Share Of The North American Leukopaks Market In 2020
4.7 Leukopaks Market: Geographic Mix
Figure 32 China To Witness The Highest Growth During The Forecast Period
4.8 Regional Mix: Leukopaks Market
Figure 33 Apac Market To Witness The Highest Growth

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 34 Leukapheresis Market: Drivers, Restraints, Opportunities, And Challenges
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence And Prevalence Of Leukemia
Figure 35 Incidence And Mortality Rates Of Leukemia, By Region, 2020
5.2.1.2 Increasing Number Of Blood Donations
Table 3 Collection Of Whole Blood Units, By Country, 2015–2016 (Million Units)
5.2.1.3 Demand For Leukopaks In Clinical Research
Figure 36 Growth In The Number Of Car-T Clinical Trials
5.2.2 Market Restraints
5.2.2.1 High Cost Of Therapeutic Leukapheresis And Leukopaks
Table 4 Cost Of Leukopaks, By Type
5.2.2.2 Stringent Donor Recruitment Criteria
Table 5 Donor Selection Criteria
Table 6 Frequency Of Blood Donations From Healthy Donors
5.2.2.3 Dearth Of Skilled Professionals And Low Adoption Of Therapeutic Leukapheresis
5.2.2.4 Complications Associated With Therapeutic Leukapheresis
5.2.2.5 Long Procedural Time For Leukapheresis
5.2.2.6 High Cost Of Cellular Immunotherapies & Lack Of Favorable Reimbursement
5.2.3 Market Opportunities
5.2.3.1 Leukapheresis For Pediatric Patients
5.2.3.2 Emerging Economies And Increasing Investments From Academic Institutes, Pharma-Biotech Companies, And Leading Players
5.2.4 Market Challenges
5.2.4.1 Blood Transfusion Safety In Developing Countries
5.3 Porter’s Five Forces Analysis
Figure 37 Porter’s Five Forces Analysis (2020): Leukapheresis Market
Table 7 Leukapheresis Market: Porter’s Five Forces Analysis
5.3.1 Threat From New Entrants
5.3.2 Threat From Substitutes
5.3.3 Bargaining Power Of Suppliers
5.3.4 Bargaining Power Of Buyers
5.3.5 Intensity Of Competitive Rivalry
5.4 Leukopaks: Pricing Analysis
Table 8 Asp Of Non-Mobilized Leukopaks
Table 9 Asp Of Mobilized Leukopaks
Table 10 Asp Of Mobilized Isolated Cells
5.5 Regulatory Analysis (Leukapheresis Products Market)
5.5.1 North America
5.5.1.1 Us
5.5.1.2 Canada
5.5.2 Europe
5.5.3 Asia Pacific
5.5.3.1 Japan
5.6 Regulatory Analysis (Leukopaks Market)
5.6.1 Us
Table 11 List Of Fda-Approved Car-T Therapeutics
5.6.2 Europe
5.6.3 Japan
5.6.4 China
5.6.5 India
5.7 Value Chain Analysis
Figure 38 Value Chain: Leukapheresis Market (Leukapheresis Systems)
5.8 Ecosystem Map
Table 12 Leukapheresis Market: Ecosystem
Figure 39 Leukapheresis Market: Ecosystem Map (2020)
5.9 Patent Analysis
5.9.1 Patent Publication Trends In The Leukapheresis Market
Figure 40 Global Patent Publication Trends In The Leukapheresis Market, 2015–2020
5.9.2 Top Applicants (Companies) For Leukapheresis Patents
Figure 41 Top Applicant Companies For Leukapheresis Patents, 2015–2020
5.9.3 Jurisdiction Analysis: Top Applicants (Countries) For Leukapheresis Market Patents
Figure 42 Jurisdiction Analysis: Top Applicant Countries For Leukapheresis Patents, 2015–2020
5.10 Technology Analysis
5.10.1 Key Markets For Import And Export (Trade Analysis For Apheresis-Related Products & Equipment)
5.10.1.1 Us
Table 13 Us: Number Of Exports Related To Apheresis Products
5.10.1.2 Russia
Table 14 Russia: Number Of Exports Related To Apheresis Products
5.10.1.3 China
Table 15 China: Number Of Exports Related To Apheresis Products

6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Increasing Number Of Collaborations Among Pharma And Biotech Companies
Table 16 Recent Pharma-Biotech Collaborations For Car-T Therapy
6.2.2 Introduction Of Customizable Cryopreserved Leukopaks
6.2.3 Use Of Leukapheresis In Clinical Trials To Determine Changes In Cellular Immune Profiles In Covid-19 Infections

7 Leukapheresis Products Market, By Type
7.1 Introduction
Table 17 Leukapheresis Products Market, By Type, 2019–2026 (Usd Million)
Table 18 Leukapheresis Products Market, By Country, 2019–2026 (Usd Million)
7.2 Leukapheresis Disposables
7.2.1 Recurrent Usage And Demand For Disposables Boosting The Growth Of This Segment
Table 19 Manufacturers Of Leukoreduction Filters
Table 20 Manufacturers Of Leukapheresis Columns & Cell Separators
Table 21 Leukapheresis Disposables Market, By Country, 2019–2026 (Usd Million)
7.3 Leukapheresis Devices
Table 22 Leukapheresis Devices Market, By Type, 2019–2026 (Usd Million)
Table 23 Leukapheresis Devices Market, By Country, 2019–2026 (Usd Million)
7.3.1 Centrifugal Devices
7.3.1.1 Increasing Installation Of Centrifugal Apheresis Devices In Hospitals For Therapeutic Apheresis To Drive Market Growth
Table 24 List Of Centrifugal Apheresis Devices Available In The Market
Table 25 Centrifugal Apheresis Devices Market, By Country, 2019–2026 (Usd Million)
7.3.2 Membrane Separators
7.3.2.1 Difficulties In Separating Huge Volumes Of Plasma From Milliliters Of Whole Blood—A Key Factor Limiting The Adoption Of These Devices
Table 26 List Of Membrane Separators Available In The Market
Table 27 Membrane Separators Market, By Country, 2019–2026 (Usd Million)

8 Leukapheresis Products Market, By Application
8.1 Introduction
Table 28 Leukapheresis Products Market, By Application, 2019–2026 (Usd Million)
8.2 Research Applications
8.2.1 Increasing Number Of Clinical Trials To Drive The Growth Of This Segment
Table 29 Leukapheresis Market For Research Applications, By Country, 2019–2026 (Usd Million)
8.3 Therapeutic Applications
8.3.1 Increasing Adoption Of Leukapheresis Procedures As A Supportive Treatment In Leukemia To Drive Market Growth
Table 30 Leukapheresis Products Market For Therapeutic Applications, By Country, 2019–2026 (Usd Thousand)

9 Leukapheresis Products Market, By End User
9.1 Introduction
Table 31 Leukapheresis Products Market, By End User,2019–2026 (Usd Million)
9.2 Blood Component Providers & Blood Centers
9.2.1 Blood Component Providers & Blood Centers Are The Largest End Users Of Leukapheresis Products
Table 32 Leukapheresis Products Market For Blood Component Providers & Blood Centers, By Country, 2019–2026 (Usd Million)
9.3 Academic & Research Institutes
9.3.1 Collaborations Between Pharmaceutical Companies And Academic & Research Institutes Will Drive Market Growth
Table 33 Leukapheresis Products Market For Academic & Research Institutes, By Country, 2019–2026 (Usd Million)
9.4 Pharmaceutical & Biotechnology Companies
9.4.1 Increasing Number Of Clinical Trials To Drive The Growth Of This End-User Segment
Table 34 Leading Pharma-Biotech Companies Involved In The Development Of Car T-Cell Technologies
Table 35 Leukapheresis Products Market For Pharmaceutical & Biotechnology Companies, By Country, 2019–2026 (Usd Million)
9.5 Hospitals & Transfusion Centers
9.5.1 Growth In The Number Of Hospitals Performing Transfusion To Drive Market Growth
Table 36 Leukapheresis Products Market For Hospitals & Transfusion Centers, By Country, 2019–2026 (Usd Million)

10 Leukopaks Market, By Type

Enquire Here for, Report Enquiry, Discount and Customization at: https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1612511

Contact Us:

Corporate Headquarters
Tower B5, office 101,
Magarpatta SEZ,
Hadapsar, Pune-411013, India
+ 1 888 391 5441
sales@reportsandreports.com

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

This release was published on openPR.